Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice.
about
Interleukin-15 responses to aging and unloading-induced skeletal muscle atrophyCorticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceSerum and muscle interleukin-15 levels decrease in aging mice: correlation with declines in soluble interleukin-15 receptor alpha expressionAntibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice.Functional β-adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiationPreclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.Cancer cachexia: medical management.Treatment of cachexia in oncologyTargeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis.Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanismCytokines in idiopathic inflammatory myopathies.Role of IL-15 in Sepsis-Induced Skeletal Muscle Atrophy and Proteolysis.Systemic elevation of interleukin-15 in vivo promotes apoptosis in skeletal muscles of young adult and aged ratsInterleukin-15 and interleukin-15R alpha SNPs and associations with muscle, bone, and predictors of the metabolic syndromeOversecretion of interleukin-15 from skeletal muscle reduces adiposityTranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice.From anabolic to oxidative: reconsidering the roles of IL-15 and IL-15Rα in skeletal muscle.Characterization and regulation of mechanical loading-induced compensatory muscle hypertrophy.Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy.Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes.Muscle-specific deletion of exons 2 and 3 of the IL15RA gene in mice: effects on contractile properties of fast and slow muscles.Overexpression of interleukin-15 in mice promotes resistance to diet-induced obesity, increased insulin sensitivity, and markers of oxidative skeletal muscle metabolismInsulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.Intramuscular beta2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury.Stimulation of calcineurin Aalpha activity attenuates muscle pathophysiology in mdx dystrophic mice.Effects of beta-hydroxy-beta-methylbutyrate (HMB) on the expression of ubiquitin ligases, protein synthesis pathways and contractile function in extensor digitorum longus (EDL) of fed and fasting rats.Notexin causes greater myotoxic damage and slower functional repair in mouse skeletal muscles than bupivacaine.Increased Number of Circulating CD8/CD26 T Cells in the Blood of Duchenne Muscular Dystrophy Patients Is Associated with Augmented Binding of Adenosine Deaminase and Higher Muscular Strength Scores.Beta hydroxy beta methylbutyrate supplementation impairs peripheral insulin sensitivity in healthy sedentary Wistar rats.
P2860
Q28581408-0926547B-E6F4-416B-99D4-90FF27363C63Q33290644-200F3378-8C4A-4F6B-8FD3-B741B4C01FAFQ33624343-AA03D2D4-539F-470F-95E7-A7957200AAE0Q33816426-F61FE09D-16E7-4588-86CA-63CAA273915FQ33855954-C893E9A2-D0EB-4810-8070-B3CA99ED305BQ33975979-5B61A5F3-ABC3-42D1-85B3-9B79276BFABEQ34018994-A1B5C950-4081-4A54-8FE7-414650A233AFQ34158188-AE45F6B2-2DCD-44ED-93A6-136DBB15EC88Q34756106-75FCEE4A-07CE-40B8-8900-0D71CD901799Q36007403-04A393B3-CED1-4E95-B968-84CF4011E5A3Q36096978-9B7CDE85-9170-4EF4-8E0E-36C88F05C9D9Q36288649-014EA4C1-B964-4CF9-B498-EDE4A572E6F7Q36504371-7CC8B164-C786-48F6-9104-A3FFE74F70CBQ36512051-BEC598F2-1A8B-4E9B-9968-679F3375B702Q36942445-D06A2687-86C7-472E-A4ED-E1727FE1963CQ36995886-E9208209-45D1-496C-B2D3-95B573E3FB67Q37086430-1F0B298C-6234-42E6-A81E-086893A2D8C1Q37539643-0AE40DF5-3178-460F-B714-613DD5595BD0Q37653077-992B07FE-FF6A-4621-AF8B-B92BDDD1B326Q38110504-8291CDB3-2464-4485-95B8-C6303F79AE7AQ38168509-A1E96611-0F03-4AD5-A6AB-367FB82A59A6Q39663447-8AD702A7-BCF8-40A1-96DB-E959EFBC891AQ41693317-6DDD297A-1546-4C64-AD2A-EC63D07D52E0Q41714051-3BECCE32-A923-40B2-A65B-15F0093DFF5EQ46528995-CE76CD85-1CE8-4EB7-8702-F752BD7335D3Q46626845-FCADDBDD-3E9D-4984-AE5E-25AC25274F82Q46805060-DCDFDE4C-35F0-4E8D-8C5A-3DCE001DBC50Q48355678-3F6FE2A9-C0AA-4518-BE05-D07035718DC2Q48675919-EAD25532-6E43-40EA-94F4-E4A5A2DF6710Q49220622-C4802089-F955-4958-8A32-C5859C3D348AQ54200939-717B27E9-A699-48A0-8BE4-A74A51B14363
P2860
Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@ast
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@en
type
label
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@ast
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@en
prefLabel
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@ast
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@en
P2093
P2860
P1476
Interleukin-15 administration ...... nction in dystrophic mdx mice.
@en
P2093
Anna Greer Holmes
David R Plant
Gordon S Lynch
Jonathan D Schertzer
Leah J Harcourt
Nicole Stupka
Paul Gregorevic
P2860
P304
P356
10.1016/S0002-9440(10)62333-4
P407
P577
2005-04-01T00:00:00Z